Publications by authors named "M Lanier"
Article Synopsis
- The human MRGPRD protein is part of a family of receptors that play a key role in detecting pain and itch, but it's not well-researched and has few known activating compounds.
- The study identifies two new potent agonists, EP-2825 and EP-3945, that are about 100 times more effective than the previously known agonist, β-alanine.
- The researchers also explored the structures of MRGPRD bound to these agonists, revealing unique binding interactions and flexibility in the receptor, which could help in creating new drugs targeting MRGPRD.
Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists.
J Allergy Clin Immunol
October 2024
Background: Mas-related G protein-coupled receptor X2 (MRGPRX2) is a promiscuous receptor on mast cells that mediates IgE-independent degranulation and has been implicated in multiple mast cell-mediated disorders, including chronic urticaria, atopic dermatitis, and pain disorders. Although it is a promising therapeutic target, few potent, selective, small molecule antagonists have been identified, and functional effects of human MRGPRX2 inhibition have not been evaluated in vivo.
Objective: We sought to identify and characterize novel, potent, and selective orally active small molecule MRGPRX2 antagonists for potential treatment of mast cell-mediated disease.
Purpose: This study evaluates the prognostic value of CT findings, including volumetric measurements, in predicting outcomes for patients with Fournier gangrene (FG), focusing on mortality, ICU admission, hospital stay length, and healthcare costs.
Methods: A retrospective study was conducted on 38 FG patients who underwent CT scans before surgical debridement. We analyzed demographic data, CT volumetric measurements, and clinical outcomes using logistic and linear regression models.